
    
      Because the activity of lenalidomide addresses numerous mechanisms of carcinoma growth
      inhibition - including, but not limited to anti-angiogenesis - lenalidomide is being
      evaluated as part of induction chemotherapy regimens for solid tumors. This phase II study in
      previously untreated metastatic pancreatic cancer is designed to establish and test the
      appropriate lenalidomide dose and regimen in combination with gemcitabine.
    
  